# Chapter 22: Diabetic Nephropathy

[← Table of Contents](https://urinenephrology.org/nephrology-textbook/index.html) [← Previous: Chapter 21](https://urinenephrology.org/nephrology-textbook/chapters/chapter-18-cardiorenal.html) [Next: Chapter 23 →](https://urinenephrology.org/nephrology-textbook/chapters/chapter-20-medications.html)

### 📖 Ready for a Deeper Dive?

Explore these related Lecture Series modules and Clinical Mastery reviews:

[🏆 Mastery: DKD Treatment](https://urinenephrology.org/mastery/ckd-advanced/dkd-treatment.html) [🏆 Mastery: GLP-1 Guide](https://urinenephrology.org/mastery/cardiorenal/glp1-guide.html)

## Chapter 22: Diabetic Nephropathy

### Understanding Diabetic Nephropathy as a Progressive Disease

Diabetic nephropathy is the leading cause of CKD and ESRD, affecting nearly 40% of patients with diabetes. It progresses through predictable stages.

#### Stage 1: Hyperfiltration

GFR increases 20-40% above normal. Kidneys enlarge. Clinically silent.

#### Stage 2: Silent Phase

GFR normalizes, but structural changes like basement membrane thickening begin.

#### Stage 3: Microalbuminuria

First clinical sign (albumin 30-300 mg/day). Represents the last potentially reversible stage.

#### Stage 4: Overt Proteinuria

Protein \>300 mg/day. GFR begins to decline steadily.

#### Stage 5: End-Stage Renal Disease

GFR \<15 mL/min/1.73m², requiring RRT.

### Comprehensive Management Approach

Management involves a multi-pronged approach:

- **Glucose Control:** Target HbA1c \<7%.
- **Blood Pressure Control:** Target \<130/80 mmHg.
- **RAAS Inhibition:** First-line therapy with ACE inhibitors or ARBs.
- **SGLT2 Inhibitors:** Now a cornerstone of therapy for both kidney and cardiovascular protection.
- **GLP-1 Agonists & Finerenone:** Emerging protective therapies.

[← Table of Contents](https://urinenephrology.org/nephrology-textbook/index.html) [← Previous: Chapter 21](https://urinenephrology.org/nephrology-textbook/chapters/chapter-18-cardiorenal.html) [Next: Chapter 23 →](https://urinenephrology.org/nephrology-textbook/chapters/chapter-20-medications.html) [↑](https://urinenephrology.org/nephrology-textbook/chapters/chapter-19-diabetic.html#top)

## 📚 Sources — Chapter 19 (Diabetic Nephropathy)

1.  Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int*. 2022;102(5S):S1-S127. [DOI](https://doi.org/10.1016/j.kint.2022.06.008) \| [PubMed](https://pubmed.ncbi.nlm.nih.gov/36272764/)
2.  **Perkovic V, et al; CREDENCE.** Canagliflozin in T2D nephropathy. *N Engl J Med.* 2019;380(24):2295-2306. [PMID: 30990260](https://pubmed.ncbi.nlm.nih.gov/30990260/).
3.  **Heerspink HJL, et al; DAPA-CKD.** Dapagliflozin in CKD. *N Engl J Med.* 2020;383(15):1436-1446. [PMID: 32970396](https://pubmed.ncbi.nlm.nih.gov/32970396/).
4.  **Bakris GL, et al; FIDELIO-DKD.** Finerenone in T2D-CKD. *N Engl J Med.* 2020;383(23):2219-2229. [PMID: 33264825](https://pubmed.ncbi.nlm.nih.gov/33264825/).
5.  **Pitt B, et al; FIGARO-DKD.** Finerenone CV outcomes. *N Engl J Med.* 2021;385(24):2252-2263. [PMID: 34449181](https://pubmed.ncbi.nlm.nih.gov/34449181/).
6.  **Perkovic V, et al; FLOW.** Semaglutide in T2D-CKD. *N Engl J Med.* 2024;391(2):109-121. [PMID: 38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/).
7.  **Brenner BM, et al; RENAAL.** Losartan in T2D nephropathy. *N Engl J Med.* 2001;345(12):861-869. [PMID: 11565518](https://pubmed.ncbi.nlm.nih.gov/11565518/).


---

[Website version](https://urinenephrology.org/nephrology-textbook/chapters/chapter-19-diabetic.html) · Markdown synchronized October 3, 2026.